Abstract
The low-molecular-weight range of the circulatory proteome is termed the 'peptidome', and could be a rich source of cancer-specific diagnostic information because it is a 'recording' of the cellular and extracellular enzymatic events that take place at the level of the cancer-tissue microenvironment. This new information archive seems to mainly exist in vivo, bound to high-abundance proteins such as albumin.Measuring panels of peptidome markers might be more sensitive and specific than conventional biomarker approaches. We discuss the advantages and disadvantages of various methods for studying the peptidome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Diamandis, E. P. Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin. Chem. 49 1272–1275 (2003).
Diamandis, E. P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer. Inst. 96, 353–356 (2004).
Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–577 (2002).
Petricoin, E. F. et al. Serum proteomic patterns for detection of prostate cancer. J. Natl Cancer Inst. 94, 1576–1578 (2002).
Petricoin, E. F., Fishman, D. A., Conrads, T. P., Veenstra, T. D. & Liotta, L. A. Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics 4, 2357–2360 (2004).
Liotta, L. A., Ferrari, M. & Petricoin E. F. Clinical proteomics: written in blood. Nature 425, 905 (2005).
Tirumalai, R. S. et al. Characterization of the low molecular weight human serum proteome. Mol. Cell Proteomics 2, 1096–1103 (2003).
Lowenthal, M. S. et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin. Chem. 51, 1933–1945 (2005).
Zhou, M. et al. An investigation into the human serum 'interactome'. Electrophoresis 25, 1289–1298 (2004).
Lopez, M. F. et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin. Chem. 51, 1946–1954 (2005).
Brouwers, F. M. et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr. Relat. Cancer 12, 263–272 (2005).
Ornstein, D. K. et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J. Urol. 172, 1302–1305 (2004).
Villanueva, J. et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116, 271–284 (2006).
Adam, B. L. et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distin-guishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609–3614 (2002).
Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y. & Chan, D. W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296–1304 (2002).
Zhukov, T. A., Johanson, R. A., Cantor, A. B., Clark, R. A. & Tockman, M. S. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 40. 267–279 (2003).
Ebert, M. P. et al. Identification of gastric cancer patients by serum protein profiling. J. Proteome Res. 3, 1261–1266 (2004).
Villanueva, J. et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal. Chem. 76, 1560–1570 (2004).
Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4, 437–450 (2003).
Stone, J. H. et al. Wegener's Granulomatosis Etanercept Trial Research Group. A serum proteomic approach to gauging the state of remission in Wegener's granuloma-tosis. Arthritis Rheum. 52, 902–910 (2005).
Zhang, Z. et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882–5890 (2004).
Traub, F. et al. Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab Invest. 86, 246–253 (2006).
Schulz-Knappe, P., Schrader, M. & Zucht, H. D. The peptidomics concept. Comb. Chem. High Throughput Screen 8, 697–704 (2005).
Diamandis, E. P. Peptidomics for cancer diagnosis: present and future. J. Proteome Res. 9, 2079–2082 (2006).
Liotta, L. A. & Kohn E. D., The microenvironment of the tumour-host interface. Nature 411, 375–379 (2001).
Culp, W. D. et al. Proteomic analysis of tumor establish-ment and growth in the B16-F10 mouse melanoma model. J. Proteome Res. 2, 1332–1343 (2006).
Jodele, S., Blavier, L., Yoon, J. M. & Declerck, Y. A. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 25, 35–43 (2006).
Hagendoorn, J. et al. Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. Cancer Res. 66, 3360–3364 (2006).
Skates, S. J. et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15–3, CA 72–4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J. Clin. Oncol. 22, 4059–4066 (2004).
Mehta, A. I. et al. Biomarker amplification by serum carrier protein binding. Dis. Markers 19, 1–10 (2003–2004).
Liotta, L. A. & Petricoin, E. F. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J. Clin. Invest. 116, 26–30 (2006).
Zheng, X., Baker, H. & Hancock, W. S. Analysis of the low molecular weight serum peptidome using ultra-filtration and a hybrid ion trap-Fourier transform mass spectrometer. J. Chromatogr. A. 1120, 173–184 (2006).
Anderson, N. L. & Anderson, N. G. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1, 845–867 (2002).
Deutsch, E. W. et al. Human plasma peptideatlas. Proteomics. 5, 3497–3500 (2005).
Rai, A. J. et al. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 5, 3467–3474 (2005).
Hortin, G. L. The MALDI TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 52, 1223–1237 (2006).
Omenn, G. S. et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 5, 3226–3245 (2005).
Shen, Y. et al. Characterization of the human blood plasma proteome. Proteomics 5, 4034–4045 (2005).
Wasinger, V. C. et al. Two-dimensional liquid chromatography/tandem mass spectrometry analysis of Gradiflow fractionated native human plasma. Proteomics 5, 3397–3401 (2005).
Yang, Z., Hancock, W. S., Chew, T. R. & Bonilla, L. A study of glycoproteins in human serum and plasma reference standards (HUPO) using multilectin affinity chromatography coupled with RPLC-MS/MS. Proteomics 5, 3353–3366 (2005).
Drake, R. R. et al. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol. Cell Proteomics 5, 1957–1967 (2006).
Paweletz, C. P. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981–1989 (2001).
Miller, J. C. et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3, 56–63 (2003).
Gorelik, E. et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 14, 981–987 (2005).
Nedelkov, D. & Nelson, R. W. Surface plasmon resonance mass spectrometry: recent progress and outlooks. Trends Biotechnol. 21, 301–305 (2003).
Clinical and Laboratory Standards Institute. Standards development. Clinical and Laboratory Standards Institute [online]
Chen, W. et al. Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: therapeutic efficacy and mechanism of protection against type 1 diabetes. Endocrinology 145, 627–638 (2004).
Napoli, J. L., Posch, K. P., Fiorella, P. D. & Boerman, M. H. Physiological occurrence, biosynthesis and metabolism of retinoic acid: evidence for roles of cellular retinol-binding protein (CRBP) and cellular retinoic acid-binding protein (CRABP) in the pathway of retinoic acid homeostasis. Biomed. Pharmacother. 45, 131–143 (1991).
Gaspari, M. et al. Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J. Proteome Res. 5, 1261–1266 (2006).
Terracciano, R. et al. Selective binding and enrichment for low-molecular weight biomarker molecules in human plasma after exposure to nanoporous silica particles. Proteomics 6, 3243–3250 (2006).
Govorukhina, N. I. et al. Analysis of human serum by liquid chromatography-mass spectrometry: Improved sample preparation and data analysis. J. Chromatogr. A. 1120, 142–150 (2006).
Yocum, A. K., Yu, K., Oe, T. & Blair, I. A. Effect of immunoaffinity depletion of human serum during proteomic investigations. J. Proteome Res. 4, 1722–1731 (2005).
Martosella, J., Zolotarjova, N., Liu, H., Nicol, G. & Boyes, B. E. Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J. Proteome Res. 4, 1522–1537 (2005).
Echan, L. A., Tang, H. Y., Ali-Khan, N., Lee, K. & Speicher, D. W. Depletion of multiple high-abundance proteins improves protein profiling capacities of human serum and plasma. Proteomics 5, 3292–3303 (2005)
Bloomston, M. et al. Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res. 66, 2592–2599 (2006).
Acknowledgements
We wish to acknowledge the significant and ongoing support of George Mason University, Fairfax, Virginia USA, and the Instituto Superiore di Sanità in Rome, Italy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
E.F.P. and L.A.L. are co-inventors on US government and University-assigned patents that cover technologies and discoveries related to the work herein. As inventors, they are entitled to receive royalties under United States law.
Related links
Related links
DATABASES
National Cancer Institute
FURTHER INFORMATION
Rights and permissions
About this article
Cite this article
Petricoin, E., Belluco, C., Araujo, R. et al. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 6, 961–967 (2006). https://doi.org/10.1038/nrc2011
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2011
This article is cited by
-
Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry
Nature Reviews Urology (2021)
-
Proteomic approaches for characterizing renal cell carcinoma
Clinical Proteomics (2020)
-
Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome
Immunogenetics (2019)
-
Recent applications of metal–organic frameworks in matrix-assisted laser desorption/ionization mass spectrometry
Analytical and Bioanalytical Chemistry (2019)
-
Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection
Nano Research (2019)